Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma.

Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Axel Hauschild(University Hospital Schleswig-Holstein), Célèste Lebbé(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Richard Kefford(Broad Institute), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Antoni Ribas(University of California, Los Angeles), Bijoyesh Mookerjee(Novartis (United States)), Felix Kiecker(Humboldt-Universität zu Berlin), Christian U. Blank(The Netherlands Cancer Institute), Matthew Squires(Novartis (United States)), Yingjie Huang, Michael Millward(University of Western Australia), Lev Demidov(Heidelberg University), Ying Zhang(Xi'an University of Architecture and Technology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)

Journal of Clinical Oncology

May 20, 2017

Cited by 6

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Investigation|2017|3.9k

|Nature Medicine|2012|3.7k

Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with <i>BRAF</i> V600–mutant melanoma.